OncLive SOSS

Authors

Tufia C. Haddad, MD

Latest:

Dr. Haddad on the Effect of Anastrozole on Endocrine Suppression in ER+/HER2- Breast Cancer

Tufia C. Haddad, MD, discusses key results from a prospective trial on adjuvant anastrozole in estrogen receptor–positive, HER2-negative breast cancer.

Thomas Cluzeau, MD, PhD

Latest:

Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.

Himachandana Atluri, MD

Himachandana Atluri, MD, is an assistant professor of medicine (Hematology and Oncology) at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois.

Latest:

Dr Atluri on TKI Selection in Chronic Myeloid Leukemia

Himchandana Atluri, MD, details factors to consider ahead of TKI selection in patients with chronic myeloid leukemia.

Victor M. Orellana-Noia, MD

Latest:

Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Gino Kim In, MD

Gino Kim In, MD, is a medical oncologist, Medical Oncology, Melanoma Surgery, Sarcoma and Melanoma Surgery and associate professor of clinical medicine at USC's Keck School of Medicine.

Latest:

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.

Kamran A. Ahmed, MD

Latest:

Dr. Ahmed on the Need for Multidisciplinary Care in HER2+ Breast Leptomeningeal Disease

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Mariam F. Eskander, MD, MPH

Latest:

Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal Cancer

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology, City of Hope

Latest:

Rethinking How We Approach Stage 3 Lung Cancer Treatment

As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.

Michael S. Leapman, MD, MHS

Latest:

Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate Cancer

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

Anita Lavery, MD, MRCP

Latest:

Dr. Lavery on the Decline in Esophageal Cancer Diagnoses in Ireland During COVID-19

Anita Lavery, MD, MRCP, discusses the decline in esophageal cancer diagnoses in Ireland during the COVID-19 pandemic.

Ryan Fecteau, MD, PhD

Latest:

Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate Cancers

Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.

Elshad Hasanov, MD, PhD

Latest:

Dr Hasanov on Actionable Immune-Resistance Targets in RCC With Brain Metastases

Elshad Hasanov, MD, PhD, discusses actionable immune-resistance targets in patients with renal cell carcinoma with brain metastases.

Virginia G. Kaklamani, MD, DSc

Virginia Kaklamani, MD, DSc, is a professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio, as well as the leader of the breast cancer program at the Mays Cancer Center, home to the UT Health San Antonio MD Anderson Cancer Center

Latest:

Dr Kaklamani on the Efficacy of Inavolisib in HR+, PIK3CA-Mutated Breast Cancer

Virginia Kaklamani, MD, DSc, discusses inavolisib's efficacy in PIK3CA-mutated metastatic breast cancer, as well as the importance of biomarker testing.

Michael K. Gibson MD, PhD

Latest:

Key Takeaways and Future Questions in Perioperative GC/GEJC

Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.

Marina Konopleva, MD

Latest:

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.

Oatile Phakathi, MBChB, FC Orth (SA), MMed

Oatile Phakathi, MBChB, FC Orth (SA), MMed is an orthopedic oncology fellow at the University of Toronoto.

Kateryna Fedorov, MD

Latest:

Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AML

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Robert Motzer, MD, Memorial Sloan Kettering Cancer Center

Latest:

Dr. Motzer on the Importance of Assessing Health-Related QOL in RCC

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

Brian Andrew Jonas, MD, PhD

Latest:

Emerging Treatment Strategies in Acute Myeloid Leukemia

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Anuradha Krishnamurthy, MBBS

Latest:

Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced Melanoma

Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.